423 related articles for article (PubMed ID: 34290907)
21. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
[TBL] [Abstract][Full Text] [Related]
22. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
Gill S; Tasian SK; Ruella M; Shestova O; Li Y; Porter DL; Carroll M; Danet-Desnoyers G; Scholler J; Grupp SA; June CH; Kalos M
Blood; 2014 Apr; 123(15):2343-54. PubMed ID: 24596416
[TBL] [Abstract][Full Text] [Related]
23. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
[TBL] [Abstract][Full Text] [Related]
24. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
25. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.
Mardiros A; Forman SJ; Budde LE
Curr Opin Hematol; 2015 Nov; 22(6):484-8. PubMed ID: 26457961
[TBL] [Abstract][Full Text] [Related]
26. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
27. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm.
Bôle-Richard E; Fredon M; Biichlé S; Anna F; Certoux JM; Renosi F; Tsé F; Molimard C; Valmary-Degano S; Jenvrin A; Warda W; Pallandre JR; Bonnefoy F; Poussard M; Deschamps M; Petrella T; Roumier C; Macintyre E; Féger F; Brissot E; Mohty M; HoWangYin KY; Langlade-Demoyen P; Loustau M; Caumartin J; Godet Y; Binda D; Pagadoy M; Deconinck E; Daguindau E; Saas P; Ferrand C; Angelot-Delettre F; Adotévi O; Garnache-Ottou F
Leukemia; 2020 Dec; 34(12):3228-3241. PubMed ID: 32111969
[TBL] [Abstract][Full Text] [Related]
28. Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape.
Xie D; Jin X; Sun R; Zhang M; Lu W; Cao X; Guo R; Zhang Y; Zhao M
Transl Oncol; 2023 Aug; 34():101695. PubMed ID: 37224766
[TBL] [Abstract][Full Text] [Related]
29. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
Baroni ML; Sanchez Martinez D; Gutierrez Aguera F; Roca Ho H; Castella M; Zanetti SR; Velasco Hernandez T; Diaz de la Guardia R; Castaño J; Anguita E; Vives S; Nomdedeu J; Lapillone H; Bras AE; van der Velden VHJ; Junca J; Marin P; Bataller A; Esteve J; Vick B; Jeremias I; Lopez A; Sorigue M; Bueno C; Menendez P
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32527933
[TBL] [Abstract][Full Text] [Related]
30. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.
El Khawanky N; Hughes A; Yu W; Myburgh R; Matschulla T; Taromi S; Aumann K; Clarson J; Vinnakota JM; Shoumariyeh K; Miething C; Lopez AF; Brown MP; Duyster J; Hein L; Manz MG; Hughes TP; White DL; Yong ASM; Zeiser R
Nat Commun; 2021 Nov; 12(1):6436. PubMed ID: 34750374
[TBL] [Abstract][Full Text] [Related]
31. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.
Pizzitola I; Anjos-Afonso F; Rouault-Pierre K; Lassailly F; Tettamanti S; Spinelli O; Biondi A; Biagi E; Bonnet D
Leukemia; 2014 Aug; 28(8):1596-605. PubMed ID: 24504024
[TBL] [Abstract][Full Text] [Related]
32. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
33. "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
Mitwasi N; Feldmann A; Arndt C; Koristka S; Berndt N; Jureczek J; Loureiro LR; Bergmann R; Máthé D; Hegedüs N; Kovács T; Zhang C; Oberoi P; Jäger E; Seliger B; Rössig C; Temme A; Eitler J; Tonn T; Schmitz M; Hassel JC; Jäger D; Wels WS; Bachmann M
Sci Rep; 2020 Feb; 10(1):2141. PubMed ID: 32034289
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Xue T; Budde LE
Hematol Oncol Clin North Am; 2020 Jun; 34(3):575-587. PubMed ID: 32336421
[TBL] [Abstract][Full Text] [Related]
35. A CD123-specific chimeric antigen receptor augments anti-acute myeloid leukemia activity of Vγ9Vδ2 T cells.
Zhang X; Ang WX; Du Z; Ng YY; Zha S; Chen C; Xiao L; Ng JY; Chng WJ; Wang S
Immunotherapy; 2022 Apr; 14(5):321-336. PubMed ID: 35152722
[No Abstract] [Full Text] [Related]
36. Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.
Pratap S; Zhao ZJ
Cancer Rep (Hoboken); 2020 Apr; 3(2):e1222. PubMed ID: 32671999
[TBL] [Abstract][Full Text] [Related]
37. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
[TBL] [Abstract][Full Text] [Related]
38. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
Jetani H; Navarro-Bailón A; Maucher M; Frenz S; Verbruggen C; Yeguas A; Vidriales MB; González M; Rial Saborido J; Kraus S; Mestermann K; Thomas S; Bonig H; Luu M; Monjezi R; Mougiakakos D; Sauer M; Einsele H; Hudecek M
Blood; 2021 Nov; 138(19):1830-1842. PubMed ID: 34289026
[TBL] [Abstract][Full Text] [Related]
39. Targeting Two Antigens Associated with B-ALL with CD19-CD123 Compound Car T Cell Therapy.
Yan LE; Zhang H; Wada M; Fang L; Feng J; Zhang W; Chen Q; Cao Y; Pinz KG; Chen KH; Petrov JC; Chen X; Leung LH; Fan XX; Senzel L; Jiang X; Ma Y; Tse W
Stem Cell Rev Rep; 2020 Apr; 16(2):385-396. PubMed ID: 31970687
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
